About Aerovate Therapeutics
Aerovate Therapeutics is a company based in Boston (United States) founded in 2018 by Benjamin T Dake. Aerovate Therapeutics has raised $75.82 million across 1 funding round from investors including Atlas Venture, Sofinnova and Osage University Partners. The company has 31 employees as of December 31, 2022. Aerovate Therapeutics offers products and services including AV-101. Aerovate Therapeutics operates in a competitive market with competitors including Actelion, Centessa Pharmaceuticals, Vivus, Biosion and CoTherix, among others.
- Headquarter Boston, United States
- Employees 31 as on 31 Dec, 2022
- Founders Benjamin T Dake
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aerovate Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$69.63 M (USD)8as on Dec 31, 2024
-
EBITDA
-$74.6 M (USD)8as on Dec 31, 2024
-
Total Equity Funding
$75.82 M (USD)
in 1 rounds
-
Latest Funding Round
$75.82 M (USD), Series A
Aug 07, 2020
-
Investors
Atlas Venture
& 2 more
-
Employee Count
31
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aerovate Therapeutics
Aerovate Therapeutics offers a comprehensive portfolio of products and services, including AV-101.
Investigational inhaled formulation for treating rare cardiopulmonary diseases.
People of Aerovate Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Aerovate Therapeutics
Aerovate Therapeutics has successfully raised a total of $75.82M through 1 strategic funding round. The most recent funding activity was a Series A round of $75.82 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aerovate Therapeutics
Aerovate Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Venture, Sofinnova and Osage University Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Aerovate Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aerovate Therapeutics
Investment portfolio details for Aerovate Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aerovate Therapeutics
Detailed financials for Aerovate Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aerovate Therapeutics Comparisons
Peer comparison for Aerovate Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aerovate Therapeutics
Aerovate Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Centessa Pharmaceuticals, Vivus, Biosion and CoTherix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for obesity and sexual health
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Inhaled therapeutics for cardiopulmonary diseases were developed and licensed.
|
Detailed competitors of Aerovate Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aerovate Therapeutics
Complete news archive for Aerovate Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aerovate Therapeutics
Aerovate Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Aerovate Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Aerovate Therapeutics is a funded company, having raised a total of $75.82M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Aerovate Therapeutics is 31.
Aerovate Therapeutics was founded in 2018 and is based in Boston, United States. Focus is placed on the biotechnology sector, where inhaled therapies for rare cardiopulmonary diseases, including pulmonary arterial hypertension, are developed. Operations center on AV-101, an inhaled dry powder formulation of imatinib designed to target diseased lung tissues directly while minimizing systemic side effects. Clinical advancement of such treatments is pursued to address unmet needs in patient care.
Aerovate Therapeutics's top competitors include Actelion, Vivus and Centessa Pharmaceuticals.
Aerovate Therapeutics offers AV-101.
Aerovate Therapeutics has 3 investors. Key investors include Atlas Venture, Sofinnova, and Osage University Partners.